329 related articles for article (PubMed ID: 18644317)
21. Splenectomy vs. rituximab as a second-line therapy in immune thrombocytopenic purpura: a single center experience.
Al Askar AS; Shaheen NA; Al Zahrani M; Al Otaibi MG; Al Qahtani BS; Ahmed F; Al Zughaibi M; Kamran I; Mendoza MA; Khan A
Int J Hematol; 2018 Jan; 107(1):69-74. PubMed ID: 28895035
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of dapsone as a second-line treatment in non-splenectomized adults with immune thrombocytopenic purpura.
Vancine-Califani SM; De Paula EV; Ozelo MC; Orsi FL; Fabri DR; Annichino-Bizzacchi JM
Platelets; 2008 Nov; 19(7):489-95. PubMed ID: 18979360
[TBL] [Abstract][Full Text] [Related]
23. Danazol therapy for chronic immune-mediated thrombocytopenic purpura in a patient with common variable immunodeficiency.
Saulsbury FT; Bringelsen KA
Am J Pediatr Hematol Oncol; 1991; 13(3):326-9. PubMed ID: 1793160
[TBL] [Abstract][Full Text] [Related]
24. Is splenectomy necessary for immune thrombocytopenic purpura? The role of rituximab in patients with corticosteroid resistance in a single-center experience.
Zhang C; Liu HF; Chen XH; Gao L; Gao L; Liu Y; Kong PY; Sun AH; Zhang X
Clin Ther; 2014 Mar; 36(3):385-8. PubMed ID: 24594069
[TBL] [Abstract][Full Text] [Related]
25. High-dose dexamethasone for splenectomy in patients with idiopathic thrombocytopenic purpura.
Bulvik S; Winder A; Ben-Tal O; Szold A; Eldor A
Haemostasis; 1998; 28(5):256-9. PubMed ID: 10420075
[TBL] [Abstract][Full Text] [Related]
26. Splenectomy for idiopathic thrombocytopenic purpura: a five-year retrospective review.
Gibson M; Sehon JK; White S; Zibari GB; Johnson LW
Am Surg; 2000 Oct; 66(10):952-4; discussion 955. PubMed ID: 11261623
[TBL] [Abstract][Full Text] [Related]
27. Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.
Jamali F; Lemery S; Ayalew K; Robottom S; Robie-Suh K; Rieves D; Pazdur R
Oncology (Williston Park); 2009 Jul; 23(8):704-9. PubMed ID: 19711585
[TBL] [Abstract][Full Text] [Related]
28. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study.
Godeau B; Porcher R; Fain O; Lefrère F; Fenaux P; Cheze S; Vekhoff A; Chauveheid MP; Stirnemann J; Galicier L; Bourgeois E; Haiat S; Varet B; Leporrier M; Papo T; Khellaf M; Michel M; Bierling P
Blood; 2008 Aug; 112(4):999-1004. PubMed ID: 18463354
[TBL] [Abstract][Full Text] [Related]
29. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura.
Zhou Z; Yang R
Crit Rev Oncol Hematol; 2008 Jan; 65(1):21-31. PubMed ID: 17681784
[TBL] [Abstract][Full Text] [Related]
30. Appropriate hospital management of adult immune thrombocytopenic purpura patients in major Italian institutions in 2000-2002: a retrospective analysis.
Cirasino L; Robino AM; Cattaneo M; Pioltelli PE; Pogliani EM; Terranova L; Morra E; Colombo P; Palmieri GA; Piscitelli P
Blood Coagul Fibrinolysis; 2010 Jan; 21(1):77-84. PubMed ID: 19858712
[TBL] [Abstract][Full Text] [Related]
31. Review article: second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults.
Lam MS
J Oncol Pharm Pract; 2010 Jun; 16(2):89-103. PubMed ID: 19525300
[TBL] [Abstract][Full Text] [Related]
32. Treatment of immune thrombocytopenic purpura in adults.
Bussel J
Semin Hematol; 2006 Jul; 43(3 Suppl 5):S3-10; discussion S18-9. PubMed ID: 16815346
[TBL] [Abstract][Full Text] [Related]
33. Reassessment of treatment modalities for paediatric patients with chronic immune thrombocytopenia.
Laws HJ; Janssen G; Borkhardt A
Hamostaseologie; 2009 May; 29(2):171-6. PubMed ID: 19404521
[TBL] [Abstract][Full Text] [Related]
34. Management of patients with refractory immune thrombocytopenic purpura.
George JN
J Thromb Haemost; 2006 Aug; 4(8):1664-72. PubMed ID: 16879206
[TBL] [Abstract][Full Text] [Related]
35. Combined romiplostim and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy.
Mitsuhashi K; Ishiyama M; Imai Y; Shiseki M; Mori N; Teramura M; Seshimo A; Motoji T
Br J Haematol; 2012 Sep; 158(6):798-800. PubMed ID: 22758388
[No Abstract] [Full Text] [Related]
36. Should medical treatment options be exhausted before splenectomy is performed in adult ITP patients? A debate.
Stasi R; Newland A; Thornton P; Pabinger I
Ann Hematol; 2010 Dec; 89(12):1185-95. PubMed ID: 20842501
[TBL] [Abstract][Full Text] [Related]
37. ITP and international guidelines: what do we know, what do we need?
Rodeghiero F; Ruggeri M
Presse Med; 2014 Apr; 43(4 Pt 2):e61-7. PubMed ID: 24656296
[TBL] [Abstract][Full Text] [Related]
38. Initial management of adults with idiopathic (immune) thrombocytopenic purpura.
George JN
Blood Rev; 2002 Mar; 16(1):37-8. PubMed ID: 11913992
[TBL] [Abstract][Full Text] [Related]
39. A follow-up study of 49 adult patients with idiopathic thrombocytopenic purpura treated with high-dose immunoglobulins and anti-D immunoglobulins.
Rodeghiero F; Schiavotto C; Castaman G; Vespignani M; Ruggeri M; Dini E
Haematologica; 1992; 77(3):248-52. PubMed ID: 1330848
[TBL] [Abstract][Full Text] [Related]
40. Management of chronic immune thrombocytopenic purpura in children and adults.
Blanchette V; Freedman J; Garvey B
Semin Hematol; 1998 Jan; 35(1 Suppl 1):36-51. PubMed ID: 9523748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
